New York State Common Retirement Fund Grows Stake in Repligen Co. (NASDAQ:RGEN)

New York State Common Retirement Fund raised its stake in Repligen Co. (NASDAQ:RGEN) by 2.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 581,442 shares of the biotechnology company’s stock after acquiring an additional 14,398 shares during the period. New York State Common Retirement Fund owned approximately 1.04% of Repligen worth $83,693,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of RGEN. Ballentine Partners LLC raised its stake in Repligen by 4.0% during the 4th quarter. Ballentine Partners LLC now owns 1,879 shares of the biotechnology company’s stock valued at $270,000 after purchasing an additional 72 shares during the period. CIBC Asset Management Inc raised its stake in Repligen by 5.0% during the 4th quarter. CIBC Asset Management Inc now owns 1,706 shares of the biotechnology company’s stock valued at $246,000 after purchasing an additional 81 shares during the period. MML Investors Services LLC raised its stake in Repligen by 2.7% during the 3rd quarter. MML Investors Services LLC now owns 3,383 shares of the biotechnology company’s stock valued at $503,000 after purchasing an additional 89 shares during the period. GAMMA Investing LLC raised its stake in Repligen by 15.2% during the 4th quarter. GAMMA Investing LLC now owns 684 shares of the biotechnology company’s stock valued at $98,000 after purchasing an additional 90 shares during the period. Finally, Louisiana State Employees Retirement System raised its stake in Repligen by 0.7% during the 4th quarter. Louisiana State Employees Retirement System now owns 14,500 shares of the biotechnology company’s stock valued at $2,087,000 after purchasing an additional 100 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on RGEN. StockNews.com raised Repligen from a “sell” rating to a “hold” rating in a research note on Friday, January 3rd. HC Wainwright decreased their price objective on Repligen from $240.00 to $180.00 and set a “buy” rating on the stock in a report on Thursday, January 23rd. Canaccord Genuity Group initiated coverage on Repligen in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective on the stock. Canaccord Genuity Group initiated coverage on Repligen in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective on the stock. Finally, TD Cowen initiated coverage on Repligen in a report on Monday, February 10th. They set a “buy” rating and a $200.00 price objective on the stock. Six research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat.com, Repligen presently has an average rating of “Moderate Buy” and an average target price of $182.91.

Repligen Stock Performance

Shares of Repligen stock opened at $150.73 on Thursday. The stock’s fifty day moving average is $155.04 and its two-hundred day moving average is $148.71. The company has a market capitalization of $8.45 billion, a PE ratio of -407.37, a price-to-earnings-growth ratio of 4.12 and a beta of 0.99. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. Repligen Co. has a 52 week low of $113.50 and a 52 week high of $207.87.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.